Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Star Therapeutics
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
Today 9:00 EDT
From
Star Therapeutics
Via
Business Wire
Star Therapeutics Receives FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VGA039 in Von Willebrand Disease Prophylaxis
April 21, 2026
From
Star Therapeutics
Via
Business Wire
Star Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12
January 05, 2026
From
Star Therapeutics
Via
Business Wire
Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting
December 06, 2025
From
Star Therapeutics
Via
Business Wire
Star Therapeutics to Present Interim Data from Phase 1/2 Multidose Study of VGA039 in von Willebrand disease at ASH Annual Meeting
November 03, 2025
From
Star Therapeutics
Via
Business Wire
Star Therapeutics Announces Oversubscribed $125 Million Series D Financing
September 30, 2025
From
Star Therapeutics
Via
Business Wire
Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)
January 06, 2025
From
Star Therapeutics
Via
Business Wire
Star Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025
From
Star Therapeutics
Via
Business Wire
Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024
December 09, 2024
From
Star Therapeutics
Via
Business Wire
Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)
June 26, 2024
From
Star Therapeutics
Via
Business Wire
Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer
January 03, 2024
From
Star Therapeutics
Via
Business Wire
Star Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Star Therapeutics
Via
Business Wire
Star Therapeutics Appoints Matthew Fust as Independent Director and Board Audit Chair
December 05, 2023
From
Star Therapeutics
Via
Business Wire
Star Therapeutics Raises $90 Million Financing to Accelerate Its Pipeline of Novel Antibody Therapies and Growth of Its Portfolio Companies
September 05, 2023
From
Star Therapeutics
Via
Business Wire
Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies
February 16, 2022
From
Star Therapeutics
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit